Skin manifestations of COVID-19 infection and peculiarities of dermatologic care of patients in the pandemic period
- Authors: Adaskevich U.P.1
-
Affiliations:
- Vitebsk State Order of Peoples’ Friendship Medical University
- Issue: Vol 22, No 7 (2020)
- Pages: 9-13
- Section: Articles
- URL: https://journals.rcsi.science/2075-1753/article/view/95322
- DOI: https://doi.org/10.26442/20751753.2020.7.200262
- ID: 95322
Cite item
Full Text
Abstract
The ongoing SARS-CoV-2 pandemic is having a huge impact on dermatological practice including the uncertainties concerning the outcome of COVID-19 infection in patients with common inflammatory disorders such as psoriasis, atopic dermatitis, autoimmune bullous diseases, the increasing need of dermatologists’ involvement in care for COVID-19 patients as well as in search for new scientific approaches to therapy of dermatological manifestations of the infection. Dermatologists all over the world are accumulating data about skin lesions which can be unnoticed symptoms of COVID-19 including various skin rashes. The article presents data by Spanish doctors who describe five various types of skin manifestations of COVID-19 as well as the results of Russian researchers about seven groups of skin eruptions in patients with COVID-19 infection depending on their etiology and mechanisms of development. SARS-CoV-2 is a new pathogen for humans that is highly contagious, can spread quickly, and is capable of causing enormous health, economic and societal impacts in setting. The consequences may continue long after the pandemic resolves, and new management modalities for dermatology may originate from the COVID-19 disaster.
Full Text
##article.viewOnOriginalSite##About the authors
Uladzimir P. Adaskevich
Vitebsk State Order of Peoples’ Friendship Medical University
Email: vitebsk.derma@mail.ru
д-р мед. наук, проф., зав. каф. дерматовенерологии Vitebsk, Republic of Belarus
References
- Gisondi P, Piaserico S, Conti A, Naldi L. Dermatologists and SARS-CoV-2: the impact of the pandemic on daily practice. J Eur Acad Dermatol Venereol 2020; 34 (6): 1196-201. doi: 10.1111/jdv.16515
- Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol 2020; 34 (5): e212-e213. doi: 10.1111/jdv.16387
- Zhang J-J, Dong X, Cao Y-Y et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 2020; 00: 1-12. doi: 10.1111/all.14238
- Jones VG, Mills M, Suarez D et al. COVID-19 and Kawasaki disease: novel virus and novel case. Hosp Pediatr 2020. doi: 10.1542/hpeds.2020-0123
- Galvan Casas C et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol 2020. doi: 10.1111/bjd.19163
- Потекаев Н.Н., Жукова О.В., Проценко Д.Н. и др. Клиническая характеристика кожных проявлений при новой коронавирусной инфекции COVID-19, вызванной SARS-CoV-2. Клин. дерматология и венерология. 2020; 21 (3).
- Kubanov AA, Deryabin DG. A New Look at the COVID-19 Pathogenesis: the Disease is a Generalized Viral Vasculitis, and the Lung Tissue Damage is a Variant of Angiogenic Pulmonary Edema. Ann Russian Academy Med Sci 2020; 75 (2): XXX. doi: 10.15690/vramn1347
- Wollenberg A, Flohr C, Simon D et al. European Task Force on Atopic Dermatitis statement on severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2)-infection and atopic dermatitis. JEADV 2020; 34: e241-290.
- https://www.psoriasiscouncil.org/blog/Statement-on-COVID-19-and-Psoriasis.htm
- Schmidt E, Kasperkiewicz M, Joly P. Pemphigus. Lancet 2019; 394: 882-94.
- Schmidt E, Zillikens D. Pemphigoid diseases. Lancet 2013; 381: 320-32.
- Russell B, Moss C, George G et al. Associations between immune-suppressive and stimulating drugs and novel COVID-19 - a systematic review of current evidence. Ecancermedicalscience 2020; 14: 102.
- Joly P, Maho-Vaillant M, Prost-Squarcioni C et al. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet 2017; 389: 2031-40.
